var data={"title":"Taliglucerase alfa (glucocerebrosidase): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Taliglucerase alfa (glucocerebrosidase): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/506570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-drug-information\" class=\"drug drug_general\">see &quot;Taliglucerase alfa (glucocerebrosidase): Drug information&quot;</a> and <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Taliglucerase alfa (glucocerebrosidase): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14279985\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elelyso</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28191124\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Elelyso</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949579\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949601\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-drug-information\" class=\"drug drug_general\">see &quot;Taliglucerase alfa (glucocerebrosidase): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pretreatment with antihistamines, antipyretics, and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with an infusion reaction requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Gaucher disease (type 1):</b> Children &ge;4 years and Adolescents: IV: 60 units/kg/dose every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from imiglucerase: Initiate taliglucerase alfa using the patient&rsquo;s same previous imiglucerase dose and administer every 2 weeks; doses may be adjusted if needed to achieve and maintain therapeutic goals. <b>Note:</b> Conversion to taliglucerase alfa is based on a single study of patients stabilized on a biweekly imiglucerase dose for &ge;6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Gaucher disease (type 1):</b> IV: 60 units/kg/dose every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from imiglucerase: Initiate taliglucerase alfa using the patient&rsquo;s same previous imiglucerase dose and administer every 2 weeks. <b>Note:</b> Conversion to taliglucerase alfa is based on a single study of patients stabilized on a biweekly imiglucerase dose for &ge;6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14279986\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elelyso: 200 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452825\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286828\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Product access is restricted to the Gaucher Personal Support (GPS) program. Healthcare providers and patients may obtain additional information by contacting the GPS program at 855-353-5976.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949583\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV infusion: Administer IV using a low protein-binding infusion set with a 0.2 micron in-line filter over a minimum of 60 minutes; usual infusion time: 60 to 120 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: Initiate infusion at a rate of 1 mL/minute; the infusion rate may be increased if tolerated, but should not exceed 2 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult patients: Initiate infusion at a rate of 1.2 mL/minute; the infusion rate may be increased if tolerated, but should not exceed 2.2 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286837\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light. Do not freeze. If not used immediately, the reconstituted solution may be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for &le;24 hours (protect from light) or at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for &le;4 hours (without protection from light). The solution diluted in NS for infusion may be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for &le;24 hours; protect from light. In total, the reconstituted and diluted products can be stored for &le;24 hours. Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949580\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of patients with a confirmed diagnosis of type 1 Gaucher disease (FDA approved in ages &ge;4 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287120\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea, vomiting (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, fixed drug eruption (type III immune-mediated; mild and intermittent), hypersensitivity reaction (antibody-positive patients and patients switching from imiglucerase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody formation (more common in adults; neutralizing but effect on therapeutic response not evaluated)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286832\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Severe hypersensitivity to taliglucerase alfa or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286833\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of IgG anti-drug antibodies (ADA) has been reported; the clinical significance is unknown. Patients who develop immune or infusion reactions to taliglucerase alfa or who have had an immune response to other enzyme replacement therapies and who are switching to taliglucerase alfa should be monitored for antibody development; it is unknown if presence of antibodies is related to a higher risk of infusion reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Dizziness and fatigue have been observed with therapy; caution patients about performing dangerous tasks (eg, driving, operating machinery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur; these reactions have occurred up to 3 hours after start of infusion. Appropriate medical support should be readily available. Base management of reaction on severity; may include slowing or temporary interruption of infusion and/or premedication (eg, antihistamine, antipyretics, corticosteroids) for mild reactions. Pretreatment may prevent subsequent reactions. Observe patient during and after infusion. If severe reactions occur, immediately discontinue infusion and initiate appropriate treatment; rechallenge with caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949600\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In a clinical trial evaluating the safety of taliglucerase alfa, treatment-na&iuml;ve pediatric patients experienced a higher incidence of vomiting compared to treatment-na&iuml;ve adults (44% vs 6%). Vomiting may be a symptom of hypersensitivity; monitor patients carefully.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395111\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395109\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=113069&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286830\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were not observed in animal reproduction studies. Pregnancy may exacerbate existing type I Gaucher disease or result in new symptoms. Women with type I Gaucher disease have an increased risk of spontaneous abortion if disease is not well controlled. Adverse pregnancy outcomes, including hepatosplenomegaly and thrombocytopenia (which may result in increased bleeding and postpartum hemorrhage requiring transfusion), may occur. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949584\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, platelet count, and chitoriosidae concentrations (baseline, every 3 months until clinical goals achieved then every 12 to 24 months or when dose changed), spleen and liver volumes and bone density (baseline, every 12 months until clinical goals achieved then every 12 to 24 months or when dose changed), ECG and echocardiogram (baseline, every 12 months until clinical goals achieved then every 12 to 24 months) (Baldellou 2004; Charrow 2004), IgG anti-drug antibody formation (in patients who experience, or previously experienced, immune or infusion reactions to enzyme replacement therapy. Monitor for hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286839\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Taliglucerase alfa is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using plant (carrot) cell culture. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide, thereby reducing liver and spleen size and improving anemia and thrombocytopenia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: Pediatric patients: 8.8 to 14.9 L; Adults: 10.7 to 11.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Pediatric patients: 33 to 37 minutes; Adults: 19 to 29 minutes (dose-dependent; increased with higher doses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49949585\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Gaucher Disease Registry:https://www.registrynxt.com/Gaucher/Pages/Home.aspx</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322936\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Elelyso Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 unit (1): $935.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25576762\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Eleliso (UA);</li>\n      <li>Elelyso (AU);</li>\n      <li>Uplyso (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baldellou A, Andria G, Campbell PE, et al, &quot;Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,&quot; <i>Eur J Pediatr</i>, 2004, 163(2):67-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/14677062/pubmed\" target=\"_blank\" id=\"14677062\">14677062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charrow J, Andersson HC, Kaplan P, et al, &quot;Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,&quot; <i>J Pediatr</i>, 2004, 144(1):112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/14722528/pubmed\" target=\"_blank\" id=\"14722528\">14722528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elelyso (taliglucerase alfa) [prescribing information]. New York, NY: Pfizer Labs; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pastores GM, Petakov M, Giraldo P, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. <i>Blood Cells Mol Dis</i>. 2014;53(4):253-260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/24950666/pubmed\" target=\"_blank\" id=\"24950666\">24950666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na&iuml;ve or previously treated with imiglucerase. <i>Blood Cells Mol Dis</i>. 2016. S1079-9796(16)30221-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/27839981/pubmed\" target=\"_blank\" id=\"27839981\">27839981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. <i>Blood Cells Mol Dis</i>. 2015;54(1):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/25453586/pubmed\" target=\"_blank\" id=\"25453586\">25453586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Morris E, Mengel E, et al, &ldquo;The Female Gaucher Patient: The Impact of Enzyme Replacement Therapy Around Key Reproductive Events (Menstruation, Pregnancy and Menopause),&rdquo; <i>Blood Cells Mol Dis</i>, 2009, 43(3):264-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/19502088/pubmed\" target=\"_blank\" id=\"19502088\">19502088</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 113069 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14279985\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28191124\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F49949579\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F49949601\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14279986\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F20452825\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F14286828\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49949583\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F14286837\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49949580\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14287120\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14286832\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14286833\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F49949600\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14395111\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14395109\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14286830\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49949584\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14286839\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F14286841\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F49949585\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322936\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25576762\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/113069|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-drug-information\" class=\"drug drug_general\">Taliglucerase alfa (glucocerebrosidase): Drug information</a></li><li><a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">Taliglucerase alfa (glucocerebrosidase): Patient drug information</a></li></ul></div></div>","javascript":null}